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ABSTRACT
Background: Respiratory viruses, including respiratory
syncytial virus (RSV), can cause asthma exacerbations
and bronchiolitis. Both conditions are associated with
enhanced cognate immune responses and inflammation
and reduced immune regulation. Lung epithelial cells
(LECs) can contribute to antiviral and allergic immune
responses while gut epithelial cells can inhibit effector T
cell responses. A study was performed to determine
whether healthy LECs regulate antigen-specific T cell
responses and if this regulation is lost during RSV
infection.
Methods: LA4 cells, a murine LEC line, infected with RSV
or primary murine LECs were co-cultured with ovalbumin-
specific T cell receptor transgenic CD4+ T cells from
DO11.10 mice and ovalbumin-pulsed bone marrow-
derived dendritic cells (DC) to assess T cell proliferation by
flow cytometry and cytokine production.
Results: The presence of LECs abrogated DC-induced T
cell proliferation and significantly reduced T cell cytokine
release. These effects of LECs were predominantly
contact-dependent, primarily affected T cells directly and
were partly mediated by transforming growth factor b.
Soluble factors and DC-mediated effects also contributed
to T cell inhibition. RSV infection of LECs reduced their
inhibitory capacity in an infection dose-dependent
manner. This was independent of proinflammatory
cytokines released by infected LECs, but in part due to
Toll-like receptor activation and to infection-induced cell
death.
Conclusion: Healthy LECs are potent inhibitors of T cell
activation, but this regulatory function is lost after RSV
infection. These findings suggest a central role for LECs in
maintaining the tolerogenic environment of healthy lungs.
Loss of this regulatory capacity after viral infection may
allow development of excessive cognate immune
responses and pulmonary inflammation.
Respiratory viruses, including respiratory syncytial
virus (RSV), are the most important triggers of
asthma exacerbations.
12 In infants, respiratory
viruses can cause severe bronchiolitis
3 which is
associated with an increased risk of asthma
development in childhood.
45 Asthma exacerba-
tions and bronchiolitis are thought to be due, at
least in part, to reduced immune regulation in the
normally tolerogenic environment of the lung and
subsequent failure to maintain tolerance to envir-
onmental antigens, resulting in excessive and
aberrant T cell responses.
6
The mucosa of the lower respiratory tract,
which mainly consists of epithelial cells, provides
a physical and functional barrier against inhaled
pathogens, allergens and particulates. In respira-
tory viral infections this barrier is breached and
lung epithelial cells (LECs) are the main port of
entry for viruses and their main site of replication.
LECs are in close contact with a variety of immune
cells including antigen-presenting cells such as
dendritic cells (DCs) and intraepithelial lympho-
cytes.
6 It has recently been recognised that LECs
can contribute to antiviral immune responses.
Upon viral infection, LECs express type 1 inter-
ferons (IFN) which induce antiviral proteins and
LEC apoptosis, activate plasmacytoid DCs and
promote cellular antiviral responses,
78as well as
proinflammatory cytokines and chemokines. In
addition, virus-infected LECs express co-stimula-
tory molecules which may modulate CD8+ T cell
responses.
9 In asthmatic airways, LECs overexpress
interleukin-13 (IL13), a Th2 cytokine that further
enhances allergic inflammation and mucus hyper-
plasia.
10 In contrast, gut epithelial cells of the colon
have been shown to inhibit CD4+ T cell prolifera-
tion.
11 It is not known whether such immune
regulatory effects of epithelial cells are unique to
the gut or whether they occur in other mucosal
sites.
These observations suggest that LECs may be
central to both the maintenance of the tolerogenic
immune environment of healthy lungs and the
switch to inflammation and increased cognate
immune responses following respiratory viral
infections. We therefore tested the hypothesis that
healthy LECs inhibit T cell activation, and that this
inhibition is lost in RSV infection.
METHODS
Detailed information is given in the online supple-
ment.
Mice
Female BALB/c mice aged 8–10 weeks (Charles
River Laboratory, Margate, UK) and DO11.10
mice
12 (The Jackson Laboratory, Bar Harbor,
Maine, USA) were housed under specific patho-
gen-free conditions and used as sources of bone
marrow-derived DCs (BM-DC) and T cell receptor
(TCR) transgenic ovalbumin (OVA)-specific CD4+
T cells (DO11.10 T cells), respectively, and under
experimental protocols approved by the Home
Office, London, UK.
Virus
Plaque-purified human RSV-A2 (LGC Promochem)
and a transgenic RSV strain expressing green
fluorescent protein (GFP-RSV)
13 (Dr M E Peeples,
Ohio Sate University) were grown in HEp-2 cells
(LGC Promochem, Teddington, Middlesex, UK).
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Bone marrow cells from femurs were cultured in the presence of
recombinant murine granulocyte-macrophage colony stimulat-
ingfactor(GM-CSF;LifeTechnologies,Paisley,UK)for10–12 days,
when resultant BM-DC were harvested.
14
Lung epithelial cells
LA4 cells, a murine lung alveolar type II epithelial cell line
15
(LGC Promochem), were grown to confluence in Ham’s F-12
medium (Invitrogen, Paisley, UK).
Primary LECs were isolated from lungs of naı ¨ve BALB/c mice by
dispase II digestion and subsequent depletion of contaminating
mononuclear cells using anti-CD45,anti-CD32/16,anti-CD31 and
anti-CD90 antibody and MACS beads (Miltenyi Biotec, Surrey,
UK).
16 Isolated primary LECs were cultured in complete RPMI
1640 medium for 3 days before use in co-culture experiments.
To assess the ability of LECs to inhibit DC-induced T cell
proliferation, LA4 cells or primary LECs (2610
5/well) were
cultured alone for 24 h, when DC/T cell co-cultures were added
directly to LECs. In some co-cultures, direct contact of LA4 cells
with DCs or T cells was prevented by Transwell chambers
(Costar, Fisher Scientific, Loughborough, UK). In antibody
neutralisation assays, LA4 cells were incubated prior to and
during co-culture with DC/T cells with anti-mouse PD-1
antibody (Clone J43, eBioscience), anti-mouse transforming
growth factor b (TGFb) (Clone 1D11, R&D Systems, Abingdon,
UK) or appropriate isotype controls.
In infection experiments, LA4 cells were inoculated with
RSV, ultraviolet-inactivated RSV (UV-RSV) or they remained
uninfected. After 24 h, LA4 cells were washed and DC/T cells
were added. To dissect the effects of RSV on the inhibitory
capacity of LECs, LA4 cells were pretreated with thymic stromal
lymphopoietin (TSLP), GM-CSF or IL6 (Invitrogen) or Toll-like
receptor (TLR) agonists: lipopolysaccharide (LPS) from E coli
serotype 055:B5, Poly I:C (both from Sigma-Aldrich, Dorset,
UK), CpG-ODN1826 (59-TCCATGACGTTCCTGACGTT-39)
or control ODN1982 (Life Technologies).
T cell proliferation assays
Following depletion of CD11c+ cells, splenic CD4+ T cells were
isolated from DO11.10 mice, both by MACS beads (Miltenyi).
Purified DO11.10 T cells (5610
5/well) were stained with carboxy
fluoroscein succinimidyl ester (CFSE) (Life Technologies), co-
cultured with BM-DC (1610
5/well) pulsed with OVA or
phosphate-buffered saline (PBS) and layered onto LECs or
medium. After 4 days, DC/T cells were harvested and reduction
in CFSE fluorescence, indicating T cell proliferation, was
determined by flow cytometry.
17 In some experiments prolifera-
tion of T cells from BALB/c mice was induced by anti-CD3
antibody and irradiated BM-DC.
Flow cytometry
Following FC receptor blockade,cells were stained with antibodies
to mouse DO 11.10-TCR, CD62L (Caltag Buckingham, UK);
Foxp3, GITR, PDL-1 and PDL-2 (all eBioscience, San Diego,
California, USA); CD4, CD25, CD3 or isotype controls (all BD
Biosciences, Oxford, UK). Samples were acquired using an LSR
flow cytometer and CellQuest software (bothBDBiosciences) and
analysed using WinList software (Verity Software).
ELISA
Cytokine concentrations in culture supernatants were assessed
using the following ELISA kits: mouse GM-CSF, TSLP and
TGFb (all R&D Systems), mouse IL6 and tumour necrosis factor
(TNFa) (both Biosource); and antibody pairs: mouse IL1, IL4,
IL5, IL10, IL12p70, IL17 and IFNc with protein standards (all BD
Biosciences). OD values at 450 nm were measured by MRXII
spectrophotometer (Dynex, Worthing, UK) with Revelation
F3.21-software (ThermoBioAnalysis SA, Santa Fe, New Mexico,
USA).
Statistical analysis
Results are expressed as mean (SEM) values. All data were
normally distributed (GraphPad Instat) and compared by
ANOVA followed by Bonferroni test if p values were
significantly different, using GraphPad Prism 4.02 (GraphPad
Software). Differences were considered to be significant at
p,0.05.
RESULTS
Effect of LECs on DC-induced T cell activation
To assess whether LECs have the ability to influence antigen-
specific T cell activation, we analysed CFSE-labelled DO11.10 T
cells that were co-cultured with OVA-pulsed BM-DC. After
4 days of culture, strong T cell proliferation was detected.
DO11.10 T cells by themselves did not proliferate. If DC and T
cells were co-cultured on confluent layers of LA4 cells, the
proliferation of DO11.10 T cells was abrogated (fig 1A). Parallel
results were obtained with primary murine LECs, which
increased the percentage of non-proliferated T cells from 38.09
(3.0)% to 96.01 (0.91)% (see online supplement). This inhibition
of T cell proliferation was independent of the DC/T cell ratio
used in co-cultures (data not shown), but did depend on LA4
cell numbers seeded at the beginning of culture (fig 1B).
Assessing T cell- and DC-derived cytokines, we found that
DO11.10 T cells, BM-DC or LA4 cells cultured alone did not
secrete cytokines with the exception of low levels of GM-CSF in
LA4 cell cultures (data not shown). In contrast, in DC/T cell co-
cultures the T cell cytokines IFNc, IL5 and IL17 and TNFa were
produced (fig 1C). The presence of LA4 cells during DC/T cell
co-cultures significantly inhibited production of these cytokines
but increased concentrations of GM-CSF and TSLP, which were
low or undetectable in the absence of LA4 cells. IL4, IL10 and
IL12 were not detected in any of the cultures.
Contribution of direct cell contact and soluble mediators to T cell
inhibition by LECs
To determine whether the inhibition of T cell proliferation by
LECs is dependent on cell contact or mediated by soluble
factors, we compared T cell proliferation after co-culture with
LA4 cells which were either in direct contact with DC/T cells or
separated from them in transwell chambers. Direct cell contact
of DC/T cell co-culture with LA4 cells completely prevented T
cell proliferation, while co-culture with LA4 cells without direct
contact but in the same medium reduced T cell proliferation by
about 30% (fig 2A).
Programmed death (PD)-ligand (PDL)-1 and PDL-2 which
bind to PD-1 on T cells and TGFb are all expressed by epithelial
cells,
91 8as confirmed here (data not shown). These molecules
have all been implicated in the inhibition of effector T cell
responses.
19 20 To determine their involvement in LEC-induced T
cell inhibition, we used blocking antibodies to PD-1 and TGFb
in LA4 cell/T cell/DC co-cultures (fig 2B). These antibodies did
not affect T cell proliferation in control cultures. In the presence
of LA4 cells, PD-1 blocking had no effect on LEC-mediated T cell
inhibition. In contrast, addition of anti-TGFb antibody, but not
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proliferation.
Mechanism of T cell inhibition by LECs
The inhibition of DC-induced T cell proliferation by LECs could
be a direct effect on T cells or mediated by DCs. To resolve this
question, BM-DCs and DO11.10 T cells were separately
cultured with LA4 cells for 24 h or exposed to control medium.
After removal of LA4 cells, DCs and T cells were co-cultured and
T cell proliferation was assessed 3 days later (fig 3A). LEC
pretreatment of both DCs and T cells or of T cells alone
markedly inhibited T cell proliferation, whereas pretreatment of
DCs only with LECs only inhibited T cell proliferation to a
small degree. This suggests that T cell inhibition by LECs is
primarily due to direct effects on T cells. To confirm this
hypothesis, we induced T cell proliferation with anti-CD3
antibody, giving the TCR signal required for activation, and
irradiated DCs that provided co-stimulatory signals but were
unable to respond to LA4 cells (fig 3B). If LA4 cells were added,
the otherwise robust T cell proliferation was prevented almost
completely, demonstrating that LECs can directly inhibit T cell
activation. This was confirmed using primary LECs (see online
supplement).
Induction of regulatory T cells (Tregs) by LECs in DC/T cell co-
cultures
We then investigated possible mechanisms for the lack of T cell
proliferation in the presence of LECs. In addition to T cell
anergy, induction of regulatory T cells (Tregs) by LECs could
inhibit T cell proliferation. We therefore examined the expres-
sion of Foxp3, a marker of Tregs, in T cells co-cultured with
DCs in the presence or absence of LA4 cells (fig 4A, B). Foxp3
was expressed both in CD25+ and CD252 CD4+ T cells (data
not shown), and the level of expression in naı ¨ve T cells did not
Figure 1 Inhibition of dendritic cell (DC)-
induced antigen-specific T cell
proliferation and cytokine production by
lung epithelial cells (LECs). (A) Carboxy
fluoroscein succinimidyl ester (CFSE)-
stained DO11.10 T cells were cultured
alone or co-cultured with ovalbumin
(OVA)-pulsed bone marrow dendritic cells
(BM-DC) (ratio 5:1) in the presence or
absence of LA4 cells (5610
5 cells per
well). DC-induced T cell proliferation was
assessed by flow cytometry measuring
CFSE dilution, shown here in dot plots.
The percentages indicate non-proliferated
T cells. (B) DC/T cells were co-cultured
with increasing numbers of LA4 cells
(+:1 6, ++:2 6, +++:4 6, ++++:6 610
5
cells per well) and T cell proliferation was
assessed and shown as percentages of
non-proliferated T cells. (C) Cytokine
concentrations in supernatants of these
co-cultures were quantified by ELISA. The
graphs show mean (SEM) values from a
representative experiment (six samples
per group) of three independent
experiments. Significant differences
indicated by horizontal bars; **p,0.01.
GM-CSF, granulocyte-macrophage colony
stimulating factor; IFNc, interferon c;
IL, interleukin; TNFa, tumour necrosis
factor a; TCR, T cell receptor; TSLP,
thymic stromal lymphopoietin.
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cells were added directly to these cultures, the percentage of
Foxp3+ DO11.10 T cells trebled. In the absence of direct contact
of DC/T cells with LECs in transwell cultures, the induction of
Foxp3+ DO11.10 T cells was less pronounced (from 4.5 (0.2)%
to 8.1 (0.5)%, p,0.05, n=6). Furthermore, expression of
glucocorticoid-induced tumour necrosis factor receptor
(GITR), another marker of Tregs, was increased in T cells after
exposure to LA4 cells (see online supplement). These findings
indicate that LECs induced cells with a Treg phenotype. To
determine whether LEC-exposed T cells, which contain the
Foxp3+ population, have immunosuppressive activity, we
assessed their influence on T cell proliferation in secondary
DC/T cell co-cultures (fig 4C). DO11.10 T cells were stimulated
to robust proliferation by BM-DC and this remained unchanged
after addition of control T cells from DC/T cell cultures without
LECs. In contrast, addition of T cells exposed to LA4 cells
significantly inhibited T cell proliferation in secondary cultures,
indicating the presence of functional Tregs. In keeping with the
inhibitory function of Tregs, CD62L was upregulated in DC/T
cell co-cultures in the presence of LECs (see online supplement),
indicating suppression of T cell activation.
Effect of RSV infection of LA4 cells on T cell inhibitory capacity
LECs are the primary target for RSV infection in the lower
respiratory tract, which leads to enhanced T cell responses and
inflammation. We therefore examined whether RSV infection
of LECs interferes with their ability to inhibit T cell activation
and proliferation. Having ascertained that LA4 cells can be
infected with RSV using GFP-RSV (see online supplement), we
infected subconfluent LA4 cells with increasing doses of RSV
(MOI of 0.1, 1 and 10), added DC/T cell co-cultures to these
24 h later and assessed T cell proliferation after another 72 h
(fig 5). Inhibition of T cell proliferation was almost complete in
the presence of LA4 cells sham infected with UV-RSV, whereas
infection with live RSV decreased LEC-induced inhibition of T
cell proliferation in an infection dose-dependent manner. After
infection of LA4 cells with RSV at an MOI of 0.1 and 1, T cell
Figure 2 Contribution of direct cell contact and soluble mediators to T
cell inhibition by lung epithelial cells (LECs). (A) Dendritic cell (DC)/T cell
co-cultures were performed alone, in direct contact with LA4 cells or in
transwell plates separating LA4 cells from DCs and T cells. (B) Blocking
antibodies to PD-1 and transforming growth factor b (TGFb) were added
at different concentrations to co-cultures of DCs, T cells and LA4 cells. In
both experiments, T cell proliferation was assessed after 4 days. The
graphs show mean (SEM) percentages of non-proliferated cells from a
representative experiment (six samples per group) of three independent
experiments. *p,0.05, **p,0.01.
Figure 3 Direct inhibition of T cells by lung epithelial cells (LECs) and,
to a lesser extent, via dendritic cells (DCs). (A) Ovalbumin (OVA)-pulsed
bone marrow dendritic cells (BM-DC) and carboxy fluoroscein
succinimidyl ester (CFSE)-labelled DO11.10 T cells were cultured
separately with LA4 cells (LA4 DC, LA4 T cells) or control medium
(normal DC, normal T cells) for 24 h. These DC and T cells were then co-
cultured in different combinations. (B) Irradiated BM-DC plus antimurine-
CD3 antibody were used to induce proliferation of CFSE-labelled splenic
CD4+ T cells from naı ¨ve BALB/c mice in the presence or absence of LA4
cells. In both experiments, T cell proliferation was measured after 72 h of
DC/T cell co-culture. The graphs show mean (SEM) percentages of non-
proliferated cells from a representative experiment (six samples per
group) of three independent experiments. Significant differences
indicated by horizontal bars: *p,0.05, **p,0.01.
Respiratory infection
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inhibition was lost completely.
Effect of TLR-3/-4 activation, RSV-induced cell death and
proinflammatory cytokines on T cell inhibitory capacity of LECs
RSV infection in LECs is known to activate TLR-3 through
double-stranded RNA and TLR-4 through RSV-F protein, to
induce secretion of proinflammatory cytokines and to trigger
apoptosis and cell death. To determine whether these factors
reduce the ability of LECs to inhibit T cell activation, we
initially monitored secretion of proinflammatory cytokines by
RSV-infected LECs and found that they had no effect on T cell
inhibition by LECs (see online supplement).
In separate experiments we exposed LA4 cells for 24 h to the
TLR-3 ligand poly I:C, the TLR-4 ligand LPS, or to PBS as a
control (fig 6A). CpG1826, a ligand of TLR-9 which is not
activated by RSV, was used to assess if non-viral TLR activation
of LECs also affects their T cell inhibitory capacity. LA4 cells
pretreated in this way were then used in co-cultures with DC/T
cells and T cell proliferation was assessed after 3 days. While
CpG1826 did not have any effect on the ability of LA4 cells to
inhibit T cell proliferation, exposure to either LPS or poly I:C
significantly reduced this ability and restored some degree of T
cell proliferation.
Finally, we investigated if the death of LA4 cells contributes
to the reduction in T cell inhibition after RSV infection. In co-
cultures with DCs and T cells, LA4 cells formed confluent layers
which remained intact up to 48 h after infection and still
showed more than 50% confluence at 72 h. To assess cell death
by trypan blue exclusion assay over the culture period, LA4 cells
were cultured in control medium or in conditioned medium
from DC/T cell co-cultures and infected with RSV (MOI=1)
(fig 6B). Without RSV infection, irrespective of the medium
used, the percentage of dead cells in LA 4 cultures remained low
Figure 4 Induction of regulatory T cells (Tregs) in dendritic cell (DC)/T
cells co-cultures exposed to lung epithelial cells (LECs). Naı ¨ve DO11.10 T
cells were co-cultured with ovalbumin (OVA)-pulsed bone marrow
dendritic cells (BM-DC) in the presence or absence of LA4 cells. After
48 h of culture, Foxp3 expression in DO11.10 T cells was assessed by
intracellular staining and flow cytometry. (A) Dot plots show Foxp3
expression in DO11.10 T cells. (B) Mean (SEM) percentage of Foxp3+
cells of total CD4+ T cells (after subtraction of isotype controls) from a
representative experiment of three independent experiments. Significant
differences indicated by horizontal brackets: **p,0.01. (C) To determine
if LA4 cell-primed T cells inhibit T cell proliferation, T cells were
transferred from DC/T cell co-cultures with (LA4 exposed) or without LA4
cells to secondary DC/T cell co-cultures and T cell proliferation was
measured in these secondary cultures after 4 days. The graph shows
mean (SEM) percentages of non-proliferated cells from a representative
experiment (six samples per group) of three independent experiments.
Significant differences indicated by horizontal brackets: **p,0.01.
Figure 5 Effect of respiratory syncytial virus (RSV) infection of LA4
cells on T cell inhibitory capacity. 24 h before co-culture with dendritic
cell (DC)/T cells, LA4 cells were infected with increasing doses of RSV
(MOI=0.1–10) or with ultraviolet-inactivated RSV as a control. T cell
proliferation was determined by carboxy fluoroscein succinimidyl ester
(CFSE) assay after 4 days of culture. The graph shows mean (SEM)
percentages of non-proliferated cells from a representative experiment
(six samples per group) of three independent experiments. Significant
differences indicated by horizontal brackets: **p,0.01.
Respiratory infection
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cultured in control medium had significantly lower rates of cell
death than those cultured with conditioned medium from DC/
T cell co-cultures, where the rate of cell death reached 81.29
(1.61)% by day 4. This indicates that LA4 cells are more
susceptible to RSV-induced cell death in the presence of
mediators secreted by DCs or T cells. The substantial rate of
cell death in LECs after infection probably contributed
significantly to the reduction in T cell inhibition.
DISCUSSION
This study aimed to determine whether LECs can inhibit T cell
activation and whether RSV infection prevents such an inhibition.
To model antigen-specific T cell responses, naı ¨ve DO11.10 T
cells were stimulated with OVA-pulsed BM-DC, resulting in
robust T cell proliferation.
17 Murine alveolar type II epithelial
LA4 cells
15 and primary murine LECs were used to represent
lower respiratory tract epithelial cells. Co-culture of DC/T
cells with confluent layers of LA4 cells or primary LECs
abrogated T cell proliferation and significantly reduced T cell
cytokine production, indicating that these LECs provided
inhibitory signals that prevented normal T cell activation.
Such triple co-cultures may well represent healthy lower
respiratory tract mucosa which contains T lymphocytes and
DCs and provides a tolerogenic environment, minimising
inappropriate immune response to harmless inhaled antigens
such as allergens.
6
Delineating the requirements for T cell inhibition by LECs,
we found that LECs had to be present early in co-cultures prior
to T cell activation, that the extent of T cell inhibition increased
with the duration of LEC exposure and that T cell inhibition
was not fully reversible after removal of LECs (see online
supplement). Transwell cultures preventing direct cell contact
of DC/T cells with LECs but not exposure to soluble mediators
revealed that direct contact induced almost complete T cell
inhibition, while soluble factors only reduced T cell proliferation
by 30%. This suggests either that LECs express an inhibitory
factor on their surface which is also shed into the medium, or
that a combination of independent membrane-bound and
secreted factors cause T cell inhibition.
Searching for inhibitory factors, we blocked PD-1 and TGFb
by antibody in triple co-cultures. LECs can express co-
stimulatory molecules including PDL-1 and PDL-2.
9 These bind
to PD-1 on T cells, a receptor that provides inhibitory signals
and that is implicated in Treg development and T cell
tolerance.
21 Anti-PD-1 treatment did not reduce LEC-induced
T cell inhibition, indicating that PDL-1 and PDL-2 are not
involved in the process.
TGFb is secreted by LECs
18 and is a factor in the induction of
some Treg subsets (Th3 cells).
22 Anti-TGFb treatment resulted
in partial restitution of T cell proliferation, indicating that
TGFb plays a role in T cell inhibition by LECs. Although TGFb
can be secreted and act as a soluble factor, on macrophages
and natural Tregs it is primarily active locally on the cell
surface.
20 23 This could explain the strong cell contact-
dependent inhibition and the weaker effect of soluble
mediators observed here. The limited effect of anti-TGFb
treatment on T cell inhibition may well be due to an inability
of the antibody used to neutralise TGFb secreted locally into
areas of cell-cell contact.
To determine if the effects of LECs were directly on T cells
or if they were mediated by DCs, T cells or DCs were pre-
cultured with LECs prior to DC/T cell co-cultures. In separate
experiments, T cells were stimulated with anti-CD3 antibody
and irradiated BM-DCs unable to express inhibitory factors de
novo upon LEC contact. Both approaches showed that the
inhibitory effects of LECs were primarily direct effects on T
cells. However, the pre-culture experiments also showed DC-
mediated inhibition of T cell activation by LECs. The
inhibitory effects of LECs on DCs may explain why DCs
from healthy lungs are poor inducers of effector T cell
activation.
24 25
LEC-induced T cell inhibition could be due to clonal deletion,
T cell anergy and the induction of Tregs. Clonal deletion is
unlikely to play a major role in our model since the numbers of
DO11.10 T cells—the majority of which belong to the same
transgenic OVA-specific clone—did not decline in the presence
Figure 6 Influence of Toll-like receptor (TLR) ligands and cell death on
lung epithelial cell (LEC)-induced T cell inhibition. (A) LA4 cells were
preincubated for 24 h with the following TLR ligands: lipopolysaccharide
(LPS), poly I:C and CPG1826 (all at 10 mg/ml) or phosphate-buffered saline
(PBS) as a control, washed and co-cultured with dendritic cell (DC)/T cells.
T cell proliferation was assessed after 72 h by carboxy fluoroscein
succinimidyl ester (CFSE) assay. (B) LA4 cells cultured in control medium
or conditioned medium from DC/T cell co-cultures were infected with
respiratory syncytial virus (RSV) (MOI=1)and cell viability was monitored
over 4 days by trypan blue exclusion. The graphs show mean (SEM)
percentages of (A) non-proliferated T cells or (B) percentage of dead cells
from a representative experiment (six samples per group) of three
independent experiments. Significant differences indicated by horizontal
bars (A) or vertical brackets (B): *p,0.05, **p,0.01.
Respiratory infection
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many settings is thought to be due to Tregs. Different subsets of
Tregs have been described, including naturally occurring Tregs
and inducible Tr1 and Th3 cells which mediate immune
regulation by IL10 and TGFb, respectively.
26 Expression of
Foxp3, the critical transcription factor driving Treg develop-
ment, is a hallmark of naturally occurring Tregs and has also
been demonstrated in induced Tregs.
27 Here, 4–5% of naı ¨ve or
activated T cells expressed Foxp3 and, in the presence of LECs,
the percentage of Foxp3+ T cells trebled, indicating the
induction of T cells with a regulatory phenotype. The addition
of LEC-exposed T cells from triple co-cultures to secondary DC/
T cell co-cultures significantly inhibited T cell proliferation,
demonstrating that T cells exposed to LA4 cells did indeed
contain functional Tregs. The induction of Tregs by LECs and
the finding that LEC-induced T cell inhibition is not completely
lost even if LEC contact is ended suggests that, in the healthy
lower respiratory tract, Tregs are generated which may retain
their immune suppressive effects even if they migrate out of the
mucosa to the regional lymph nodes. Here they are likely to
contribute to the maintenance of normal immune tolerance to
environmental antigens.
Since respiratory viruses are major triggers of airway
inflammation and asthma exacerbations, we examined whether
viral infection of LECs reduces their immune regulatory
function. RSV infection of LA4 cells 24 h before the addition
of DC/T cell co-cultures reduced T cell inhibition in a dose-
dependent fashion. This effect of RSV infection cannot be
explained by accidental infection of DCs, which would have
displayed a reduced ability to induce T cell proliferation.
28
If infection was mimicked by treatment of non-infected LA4
cells with poly I:C (an artificial double-stranded RNA and TLR3
agonist as it occurs during RSV replication) or LPS (a TLR4
agonist like RSV F-protein
29), T cell inhibition was significantly
reduced in subsequent DC/T cell co-cultures. This indicates that
some TLR-induced pathways in LECs reduce their ability to
inhibit T cell proliferation. In contrast, proinflammatory
cytokines from RSV-infected LECs do not change their T cell
inhibitory capacity (see online supplement).
Considering that LECs can undergo apoptosis and necrosis
during viral infection, we determined whether RSV-induced
death of LEC accounts for the reduction in T cell inhibitory
capacity. Trypan blue exclusion assays revealed that about 50%
of LA4 cells died within 4 days of RSV infection and that DC/T
cell-derived mediators rendered them even more susceptible to
RSV-induced death, suggesting that the latter contributed
significantly to the reduced T cell inhibitory capacity of LECs.
This may also apply during natural RSV infection which
induces extensive destruction of lower respiratory tract epithe-
lium.
3 In affected areas normal inhibition of T cells and DCs
may be lost, resulting in excessive local T cell responses and
subsequent inflammation. This notion is in keeping with the
enhanced T cell stimulatory capacity of pulmonary DCs
observed following RSV infection
24 and other respiratory viral
infections.
25 30
Taken together, our findings suggest that LECs inhibit T cell
activation in healthy airway mucosa and that they induce Tregs
which suppress unwanted adaptive immune responses, not only
in the mucosa but also in the associated regional lymph nodes.
Upon respiratory viral infection with, for example, RSV, the
inhibitory capacity of LECs is compromised, allowing local
activation of T cell responses in the respiratory mucosa and
consequent airway inflammation. It needs to be recognised that
these hypotheses are based on in vitro studies with murine cells.
Further studies in human LEC lines and primary LECs from
patients with and without viral infection of the lower
respiratory tract will be required to validate our findings in
the clinical setting.
In conclusion, we report that healthy LECs are potent
inhibitors of T cell activation and proliferation and associated
cytokine secretion. Our data demonstrate that (1) LECs provide
both membrane-bound and soluble inhibitory factors with
direct effects on T cells; (2)TGFb may contribute to this
inhibition; and (3) T cell inhibition is, at least in part, achieved
through the induction of Tregs. After RSV infection, the T cell
inhibitory capacity of LECs is reduced or lost depending on the
severity of the infection. This is partly due to TLR activation in
LECs and to cell death.
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A previously healthy adolescent with
evolving infiltrates and progressive
respiratory distress
CLINICAL PRESENTATION
A 14-year-old boy was transferred to our paediatric referral
centre with a 1-day history of worsening respiratory distress. He
had initially presented to a community hospital complaining of
dyspnoea, cough and emesis, and was treated with antibiotics
and methylprednisolone prior to transfer. He was taking no
other medications and his history was notable only for mild
wheezing as a young child. He lived in a rural wooded area in
the eastern USA and reported riding his motorcycle on dusty
roads. He reported inhaling second-hand cigarette smoke on the
night prior to presentation.
His temperature on presentation was 37.2uC with mild
tachycardia. His respiratory rate was 24 breaths/min with
bilateral wheezes and decreased air movement at the right base.
His oxygen saturation was 89% when breathing room air. The
initial white blood cell count was 31 230/mm
3 with 94%
neutrophils. A chest radiograph showed interstitial infiltrates in
the left upper and right lower lobes.
He was treated with antibiotics for presumptive severe commu-
nity-acquired pneumonia. His respiratory distress and hypoxaemia
worsened so he was placed on BiPAP. A subsequent chest
radiograph showed worsening bilateral infiltrates with consolida-
tion in the right middle lobe and the appearance of a pleural
effusion. Extensive testing failed to reveal an infectious cause.
Owing to his worsening clinical status, evolving infiltrates
and lack of a clear aetiology, flexible bronchoscopy with
bronchoalveolar lavage (BAL) and transbronchial biopsy was
performed 2 days after presentation. The diagnosis was
suggested by initial examination of the BAL fluid and confirmed
by further testing including histological examination (fig 1).
QUESTION
What is the aetiology of this patient’s evolving infiltrates and
worsening respiratory status?
See page 364.
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Figure 1 H&E stain of transbronchial biopsy specimen (406
magnification).
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